daratumumab biosimilar / CSPC Pharma - LARVOL DELTA

The Board of Directors (the ‘‘Board’’) of CSPC Pharmaceutical Group Limited…is pleased to announce that Daratumumab Injection (the ‘‘Product’’) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. (CSPC Press Release)

New trial • Multiple Myeloma

Daratumumab injection obtains clinical trial approval in China (HKEXnews) - "The Product, a human monoclonal IgG1 antibody binding to ADP-ribosyl cyclase (CD38), is a biosimilar to the originator drug Darzalex and has been submitted for clinical trial application as a Class 3.3 therapeutic biological product, for the treatment of adult patients with multiple myeloma."

New trial • Multiple Myeloma